Literature DB >> 29862426

Mitigation of cisplatin-induced peripheral neuropathy by canagliflozin in rats.

Ahmed A Abdelsameea1, Soad L Kabil2.   

Abstract

Peripheral nervous system neurotoxicity is the most problematic complication of cisplatin treatment. In this study, we have addressed the possible neuroprotective effect of canagliflozin on cisplatin-induced peripheral neurotoxicity in rats. Rats were randomly allocated into the following: control (vehicle) group, received hydhroxypropyl methyl cellulose; cisplatin group, injected cisplatin 2 mg/kg intraperitoneal, twice a week for 5 consecutive weeks; canagliflozin-cisplatin of received canagliflozin, 10 mg/kg/day by gavage and cisplatin in the same schedule like cisplatin group. Thermal nociception and rotarod performance were assessed. Malondialdehyde (MDA), reduced glutathione (GSH), tumor necrosis factor-α (TNF-α), and caspase 3 were determined in serum. Hematoxylin and eosin (H&E) and immunohistochemical stained sciatic nerve sections were examined. Cisplatin induced thermal hypoalgesia and decreased rotarod performance as well as GSH serum level while increased MDA, TNF-α, and caspase-3 serum levels with atrophy and fragmentation of the nerve fibers with decreased expression of myelin basic protein. Canagliflozin prevented thermal hypoalgesia and improved rotarod performance with increment in GSH serum level while decreased MDA, TNF-α, and caspase-3 levels as well as prevented fragmentation of the nerve fibers and enhanced myelin basic protein expression in relation to cisplatin group. Canagliflozin attenuates the neurotoxic effect of cisplatin through anti-inflammatory and anti-oxidant actions as well as inhibition of apoptosis.

Entities:  

Keywords:  Apoptosis; Canagliflozin; Caspase-3; Malondialdehyde; Peripheral neuropathy

Mesh:

Substances:

Year:  2018        PMID: 29862426     DOI: 10.1007/s00210-018-1521-5

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  41 in total

1.  Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate.

Authors:  F M Boyle; H R Wheeler; G M Shenfield
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Relationship of intracellular calcium and oxygen radicals to Cisplatin-related renal cell injury.

Authors:  Yoshiko Kawai; Takafumi Nakao; Naoshi Kunimura; Yuka Kohda; Munekazu Gemba
Journal:  J Pharmacol Sci       Date:  2006-01-13       Impact factor: 3.337

Review 3.  Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.

Authors:  Sherry Wolf; Debra Barton; Lisa Kottschade; Axel Grothey; Charles Loprinzi
Journal:  Eur J Cancer       Date:  2008-06-18       Impact factor: 9.162

4.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.

Authors:  Yehuda Handelsman; Robert R Henry; Zachary T Bloomgarden; Sam Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Ele Ferrannini; Vivian A Fonseca; Alan J Garber; George Grunberger; Derek LeRoith; Guillermo E Umpierrez; Matthew R Weir
Journal:  Endocr Pract       Date:  2016-06-01       Impact factor: 3.443

5.  Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor.

Authors:  G Cavaletti; G Pezzoni; C Pisano; N Oggioni; F Sala; C Zoia; C Ferrarese; P Marmiroli; G Tredici
Journal:  Neurosci Lett       Date:  2002-04-05       Impact factor: 3.046

Review 6.  DNA damage response in peripheral nervous system: coping with cancer therapy-induced DNA lesions.

Authors:  Ella W Englander
Journal:  DNA Repair (Amst)       Date:  2013-05-16

7.  The effect of repeated daily measurements on paw withdrawal latencies in Hargreaves test.

Authors:  Dragana Kocevski; Ante Tvrdeić
Journal:  Coll Antropol       Date:  2008-01

8.  An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections.

Authors:  Nicolas Authier; Jean Pierre Gillet; Joseph Fialip; Alain Eschalier; François Coudore
Journal:  Exp Neurol       Date:  2003-07       Impact factor: 5.330

Review 9.  Cisplatin-induced ototoxicity: transporters playing a role in cisplatin toxicity.

Authors:  Sofia Waissbluth; Sam J Daniel
Journal:  Hear Res       Date:  2013-03-01       Impact factor: 3.208

Review 10.  Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy.

Authors:  Aparna Areti; Veera Ganesh Yerra; Vgm Naidu; Ashutosh Kumar
Journal:  Redox Biol       Date:  2014-01-18       Impact factor: 11.799

View more
  5 in total

1.  The Neuroprotective Effect of Mesna on Cisplatin-Induced Neurotoxicity: Behavioral, Electrophysiological, and Molecular Studies.

Authors:  Somayeh Noroozzadeh; Hedieh Esmaeili; Hakimeh Saadati; Keyvan Amirshahrokhi; Javad Shadman; Ali Niapour
Journal:  Neurotox Res       Date:  2020-11-20       Impact factor: 3.911

2.  Low-intensity low-frequency pulsed ultrasound ameliorates sciatic nerve dysfunction in a rat model of cisplatin-induced peripheral neuropathy.

Authors:  Busra Bilir-Yildiz; Fatma Bahar Sunay; Hatice Fulya Yilmaz; Ozlem Bozkurt-Girit
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.379

3.  The Role of Vascular-Immune Interactions in Modulating Chemotherapy Induced Neuropathic Pain.

Authors:  Tameille Valentine; Lydia Hardowar; Jasmine Elphick-Ross; Richard P Hulse; Mark Paul-Clark
Journal:  Front Pharmacol       Date:  2022-06-22       Impact factor: 5.988

4.  Sustainable Release of Propranolol Hydrochloride Laden with Biconjugated-Ufasomes Chitosan Hydrogel Attenuates Cisplatin-Induced Sciatic Nerve Damage in In Vitro/In Vivo Evaluation.

Authors:  Yasmin M Ahmed; Raha Orfali; Doaa S Hamad; Mostafa E Rateb; Hanan O Farouk
Journal:  Pharmaceutics       Date:  2022-07-23       Impact factor: 6.525

Review 5.  Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Giulia Fumagalli; Laura Monza; Guido Cavaletti; Roberta Rigolio; Cristina Meregalli
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.